USFDA clears Lupins potassium deficiency drug
New Delhi : Drug firm Lupin said its subsidiary Gavis Pharmaceuticals has received final approval from the US health regulator to market potassium chloride extended release capsules.
It is used for treating potassium deficiency in the bloodstream, in the American market.
The US-based Gavis has received final approval from US Food and Drug Administration (USFDA) to market a generic equivalent of Actavis Labs FL Inc's potassium chloride extended release capsules in various strengths, Lupin Ltd said in a regulatory filing.
Lupin had announced acquisition of Somerset-based Gavis Pharmaceuticals on July 23 last year.
According to IMS MAT June sales data, potassium chloride extended-release capsules had US sales of $75.4 million.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd